An amidine compound represented by formula (1)
wherein R
1
, R
2
, R
3
, R
4
and R
5
are the same or different and represent a C1 to C5 alkyl group optionally having one or more halogen atoms or the like; R
6
and R
7
are a hydrogen atom or the like; R
8
and R
9
are the same or different and represent a C1 to C3 alkyl group optionally having one or more halogen atoms or the like; and R
10
and R
11
are the same or different and represent a C1 to C6 alkyl group optionally having one or more halogen atoms or the like,
has an excellent control effect on plant diseases.
Syntheses and Evaluation of Anticonvulsant Activity of Novel Branched Alkyl Carbamates
作者:Naama Hen、Meir Bialer、Boris Yagen
DOI:10.1021/jm201751x
日期:2012.3.22
2-ethyl-3-methyl-butyl-carbamate (34) and 2-ethyl-3-methyl-pentyl-carbamate (38) also exhibited potent activity in the pilocarpine-SE model 30 min postseizure onset. Extending the aliphatic side chains of homologous carbamates from 7 to 8 (34 to 35) and from 8 to 9 carbons in the homologues 38 and 43 decreased the activity in the pilocarpine-SE model from ED50 = 81 mg/kg (34) to 94 mg/kg (35) and from 96 mg/kg (38)
Cyclopropanation of Allylic Alcohols using Substituted Haloalkylzinc Reagents: Synthesis of gem-Dimethylcyclopropanes
作者:André B. Charette、Nicole Wilb
DOI:10.1055/s-2002-19345
日期:——
gem-Dimethylcyclopropanes were obtained by a cyclopropanation of allylic alcohols and ethers using a mixture of diethylzinc and 2,2-diiodopropane in 53-96% yields. Enantioenriched gem-dimethylcyclopropanes were also synthesized using a glucose-derived auxiliary.
[EN] GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES<br/>[FR] AGONISTES DE GPR40 POUR LE TRAITEMENT DU DIABÈTE DE TYPE 2
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2017027309A1
公开(公告)日:2017-02-16
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I), as follows: wherein R1, R2, R4, W, X, Y, and G, are defined herein.
PYRAZINE GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
申请人:Janssen Pharmaceutica NV
公开号:US20160009662A1
公开(公告)日:2016-01-14
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows:
wherein R
1
, G, and R
2
are defined herein.